September 29, 2016 9:45 AM ET

Chemicals

Company Overview of Q-Biologicals NV

Company Overview

Q-Biologicals NV manufactures biological substances with the help of living, biological processes. The company engages in the production and purification of proteins. Q-Biologicals NV was founded in 2011 and is based in Gent, Belgium. As of January 25, 2016, Q-Biologicals NV operates as a subsidiary of Amatsigroup.

Technology Park

Zwijnaarde

Gent,  

Belgium

Founded in 2011

Key Executives for Q-Biologicals NV

Chief Executive Officer
Compensation as of Fiscal Year 2016.

Q-Biologicals NV Key Developments

Propanc Health Group Corporation Enters into Contract Manufacturing Agreement with AmatsiQBiologicals

Propanc Health Group Corporation announced it has executed a contract manufacturing agreement with AmatsiQBiologicals. The agreement covers the development and GMP (Good Manufacturing Practice) production of certain enzymes for development purposes, including but not limited to first-in-man studies for the Company's lead product, PRP. PRP is the Company's novel, patented, formulation consisting of two proenzymes mixed in a synergistic ratio to target cancer stem cells in solid tumors. The GMP manufacture of PRP as an injectable drug product requires specialized and detailed activities to be carried out in order to meet the high quality and safety standards for future human use. It is a significant undertaking by the Company, as it demonstrates the Company's commitment to initiating first-in-man studies in 2017. Pursuant to the Manufacturing Services Agreement, Q-Biologicals will produce certain drug substances and product containing certain enzymes at its facility in Belgium. The company will use these substances and products for development purposes, including but not limited to clinical trials. The MSA contemplates payment to Q-Biologicals pursuant to a pre-determined fee schedule based on the completion of certain milestones that depend on the company's manufacturing requirements and final batch yield. The Company anticipates that its payments to Q-Biologicals under the MSA will range between $2.5 million and $5.0 million over five years, with the majority of the expenditures occurring during the first two years of the MSA when the finished drug product is manufactured and released for clinical trials, including a pre-payment to Q-Biologicals of approximately $144,000.

Q-Biologicals NV Presents at BIO-Europe 2015, Nov-02-2015

Q-Biologicals NV Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Similar Private Companies By Industry

Company Name Region
Abriso nv Europe
Acotec nv Europe
ACP Belgium N.V. Europe
Afinia Plastics N.V. Europe
Afrifina NV Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 25, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Q-Biologicals NV, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.